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Received 30 July 2007; received in revised form 31 August 2007; accepted 6 September 2007Abstract Mouse embryonic stem cells (mESC) exhibit cell cycle properties entirely distinct from those of somatic cells. Here
we investigated the cell cycle characteristics of human embryonic stem cells (hESC). HESC could be sorted into populations
based on the expression level of the cell surface stem cell marker GCTM-2. Compared to mESC, a significantly higher proportion
of hESC (GCTM-2+ Oct-4+ cells) resided in G1 and retained G1-phase-specific hypophosphorylated retinoblastoma protein (pRb).
We showed that suppression of traverse through G1 is sufficient to promote hESC differentiation. Like mESC, hESC expressed
cyclin E constitutively, were negative for D-type cyclins, and did not respond to CDK-4 inhibition. By contrast, cyclin A
expression was periodic in hESC and coincided with S and G2/M phase progression. FGF-2 acted solely to sustain hESC
pluripotency rather than to promote cell cycle progression or inhibit apoptosis. Differentiation increased G1-phase content,
reinstated cyclin D activity, and restored the proliferative response to FGF-2. Treatment with CDK-2 inhibitor delayed hESC in G1
and S phase, resulting in accumulation of cells with hypophosphorylated pRb, GCTM-2, and Oct-4 and, interestingly, a second
pRb+ GCTM-2+ subpopulation lacking Oct-4. We discuss evidence for a G1-specific, pRb-dependent restriction checkpoint in hESC
closely associated with the regulation of pluripotency.
© 2007 Elsevier B.V. All rights reserved.Introduction
Terminal differentiation of progenitor cells is accompanied
by irreversible exit from the cell cycle in the G
1
phase as the
cells acquire their definitive phenotypic characteristics.
Perhaps the best example of this intricate relationship is
provided by the retinoblastoma (Rb) gene, a master regu-
lator of G1-S cell cycle traverse (Weinberg, 1995; reviewed in⁎ Corresponding author.
E-mail address: pera@usc.edu (M.F. Pera).
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doi:10.1016/j.scr.2007.09.002Classon and Harlow, 2002), which is the essential switch
driving, for example, an undifferentiated myoblast toward
the functional myotube. In these cells, cross talk between
the muscle-specific transcription factor MyoD and phos-
phorylated Rb protein (pRb) initiates cell cycle shutdown in
G1 and promotes the downregulation of cyclins E and A.
Dephosphorylation of pRb elevates MyoD levels further,
leading to the upregulation of p21 in a positive feedback
loop to block cell cycle progression. Together with the acti-
vation of the transcription factor MEF2 and other myogenic
factors, pRb is essential for continued differentiation and
cell cycle exit that culminate into full myogenesis (reviewed.
46 A.A. Filipczyk et al.in De Falco et al., 2006; Khidr and Chen, 2006). Recently, pRb
and other “cell cycle” proteins have been implicated in the
differentiation of many stem cell types, including those
found in the eye lens, brain, peripheral nervous system,
muscle, placenta, hematopoietic system, epidermis, mela-
nocytes, hair cells, liver, prostate, lung, cerebellum, pitui-
tary, and retina (reviewed in Skapek et al., 2006).
Pluripotent embryonic stem cells (ESC), in contrast to the
progenitors, do not exit the cell cycle during their first
differentiation steps. How control of their cell cycle is then
related to differentiation is substantially less clear. Under-
standing the relationship is, however, essential if growth and
differentiation are to be properly controlled. Mouse and
primate ESC have been described previously as rapidly
dividing with a truncated G1 phase, lacking D-type cyclins
and expressing permanently hyperphosphorylated pRb (Sava-
tier et al., 1994; Stead et al., 2002; Fluckiger et al., 2006).
Human ESC (hESC) have also been described as rapidly
dividing with a truncated G1 phase but, uniquely, these cells
apparently also possess elevated expression of cyclin D2 and
CDK-4 mRNA, a feature characteristic of human ESC and
often interpreted as the responsiveness of hESC to growth
factor signaling in G1 (Becker et al., 2006, 2007).
Derived from the pluripotent cells in the inner cell mass
of the preimplantation blastocyst, both mouse and human ES
cells are in principle karyotypically normal, can be pro-
pagated indefinitely, and can differentiate into cell types
representative of all three embryonic germ layers (Pera et
al., 2000). ES cells from both species express a set of genes
characteristic of the pluripotent state, including the trans-
cription factors Nanog and Oct-4 (Pera and Trounson, 2004).
In the absence of mouse embryonic fibroblast (MEF) feeder
cells, mouse ES cells can be maintained in culture and
cloned with high efficiency in the presence of leukemia
inhibitory factor (LIF) (Smith et al., 1988; Williams et al.,
1988). MEF feeders also inhibit the differentiation of hESC,
but LIF does not support hESC self-renewal (Thomson et al.,
1998) and the cloning efficiency of these cells is very poor
(b1%) (Amit et al., 2000). HESC appear to benefit from basic
fibroblast growth factor (FGF-2) supplementation under
serum-free conditions (Amit et al., 2000; Xu et al., 2005) but
it is not clear whether FGF-2 acts directly on hESC to
stimulate proliferation, inhibit differentiation, and/or pre-
vent apoptosis or whether its effect is mediated in part
through feeder cells (Dvorak et al., 2005; Greber et al.,
2007). Thus, while ES cells from mouse or human share
attributes associated with pluripotency, they appear to
display different requirements for maintenance and growth
in vitro.
In this study we examined the cell-cycle characteristics
of hESC and documented changes in cell-cycle events that
accompanied their differentiation. Interestingly, contraryFigure 1 (a) Flow-cytometric profile showing expression of the hE
three subpopulations: GCTM-2NEG, GCTM-2LOW, and GCTM-2HIGH cell
G2/M phases of the cell cycle are quantified and represented graphica
(b) Double-label flow-cytometric analysis showing the proportions o
the stem cell marker Oct-4. Significant differences are indicated
expression of the mouse ES cell marker SSEA-1. Cells within the
SSEA-1LOW, and SSEA-1HIGH cells. For each gated population, cell p
quantified and represented in a bar graph. There were no significato previous accounts, hESC, like mESC, were negative for
cyclin D proteins and unresponsive to CDK-4 inhibitor
treatment. All stem cell marker-positive cells were cyclin
E positive, indicating constitutive expression, while cyclin A
was periodically expressed, coinciding with cell progression
through S and G2/M phases. Importantly, we found the
hypophosphorylated form of pRb present in hESC and
expressed in the G1 phase of the cell cycle. The mode of
cell cycle control in hESC appears to be different from that
of other pluripotent cell types documented so far.
Spontaneous differentiation extended the G0/G1 phase,
restored D-type cyclin activity, lowered the expression of
the CDK-2 kinase partners cyclins E and A, and increased
pRb activation. To examine whether cycle perturbation
could promote hESC differentiation, we treated hESC with a
CDK-2-specific inhibitor and successfully delayed these cells
in the G0/G1 and G2/M phases of the cell cycle. This
resulted in the accumulation of hESC positive for the G1-
specific, hypophosphorylated form of pRb, and interest-
ingly, we also found a significant increase in a cell sub-
population positive for hypophosphorylated pRb and GCTM-
2, which had lost Oct-4. We discuss evidence for a unique,
functional pRb-dependent restriction checkpoint in the
hESC G1 phase and its role in specifying the choice between
self-renewal and differentiation. In light of these findings
we also examine further the biological effects of FGF-2 in
hESC cultures.Results
Serum-free culture of hESC on MEF with FGF-2
HESC culture on MEF in serum-free medium supplemented
with FGF-2 (4 ng/ml) has been described previously (Amit et
al., 2000). We confirmed the long-term (N30 passages)
propagation of the hESC lines HES-2, HES-3, and HES-4 using
this serum-free culture system. Under these conditions, each
cell line retained typical hESC morphology (Supplementary
Figs. 1a and 1b). Immunocytochemical analysis with anti-
bodies against Oct-4 and the cell surface proteoglycan
characteristic of primate pluripotent stem cells (GCTM-2
and TRA-1-60) showed that all lines also retained stem cell
marker expression (Supplementary Figs. 1c–1h) and normal
karyotypes (Supplementary Figs. 1i and 1j), though in some
serum-free-grown cultures we have observed the emergence
of aneuploid variants (unpublished data), similar to previous
observations (Draper et al., 2004). These aneuploid cultures
were not included in this study. The cell lines used for this
study retained the ability to form teratomas in SCID mice
containing tissues representative of each of the three
embryonic germ layers (data not shown).SC marker GCTM-2. Cells within the profile are subdivided into
s. For each gated population, cell proportions in G0/G1, S, and
lly. Significant differences are indicated by asterisks (⁎⁎pb0.01).
f GCTM-2NEG, GCTM-2LOW, and GCTM-2HIGH cells colabeling with
by asterisks (⁎⁎pb0.01). (c) Flow-cytometric profile showing
profile are subdivided into three subpopulations: SSEA-1NEG,
roportions in G0/G1, S, and G2/M phases of the cell cycle are
nt differences.
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cultures
To define the cell cycle structure of hESC we developed a
flow-cytometric immunoassay simultaneously measuring the
proportions of cells in G0/G1, S, and G2/M phases of the cell
cycle (5-bromo-2 and prime;-deoxyuridine (BrdU) incorpora-
tion vs propidium iodide (PI) staining) and labeling intensity
for the hESC marker GCTM-2. This enabled the comparison of
cell cycle profiles in subpopulations of cells with different
levels of marker expression. To ensure that MEF feeder cell
contamination was minimal we quantitated cells labeling
positive for the mouse fibroblast marker Thy-1.2. The
proportion of MEF feeders in samples analyzed did not
exceed 4.2±2.1% (Supplementary Fig. 2). We analyzed cell
subpopulations that were negative (GCTM-2NEG; relative to
isotype-specific primary control), weakly positive (GCTM-
2LOW; cells±12.5% from the mean fluorescence intensity,
representing cells losing marker expression and thus differ-
entiating), and strongly positive (GCTM-2HIGH; cells in the top
25% of GCTM-2 labeling distribution, a fraction in which all
cells coexpress Oct-4) (Fig. 1a). The three cell populations
had significantly different proliferative fractions (S-phase
cells) as indicated by BrdU incorporation. The GCTM-2HIGH
population had the highest proportion of S-phase cells (52±
4.6%) and the lowest proportion of cells in G0/G1 (24±3.4%).
The GCTM-2LOW population had a significantly lower pro-
portion of cells in S phase (35±3.1%), while the percentage of
cells in G0/G1 was larger (45.3±4.9%). The population lacking
GCTM-2 expression (GCTM-2NEG cells) had the lowest S-phase
fraction (17±3.8%) and the highest proportion of cells in
G0/G1 (59.3±12.5%). No significant differences between the
three subpopulations were observed in the proportions of
cells in G2/M (23±16, 20±3.4, 24.2±3.8%). Double-label
flow-cytometric analysis experiments using GCTM-2 and Oct-
4 confirmed that 98±1.4% of GCTM-2HIGH cells were Oct-4
positive (Fig. 1b). The GCTM-2LOW and GCTM-2NEG cell
subpopulations contained significantly lower (85±3.3 and
under 5%, respectively) proportions of Oct-4-positive cells.
GCTM-2HIGH cells thus represent a subpopulation uniformly
expressing Oct-4 and other markers of hESC.
For comparison the mouse ES cell cycle was analyzed by
the same method after fractionation of the population
according to the intensity of the mouse ES cell marker SSEA-
1. We analyzed cells that were negative (SSEA-1NEG; relative
to isotype-specific primary control), weakly positive (SSEA-
1LOW; cells in the mid-25% of SSEA-1 labeling distribution),
and strongly positive (SSEA-1HIGH; cells in the top 25% of
SSEA-1 labeling distribution) for their cell cycle stage
distribution (Fig. 1c). Mouse ES cells (SSEA-1HIGH) had a
different cell cycle structure compared to their humanFigure 2 Double immunofluorescence staining for D-type cyclins
(phase contrast), (b) corresponding Oct-4 expression (red), (c) Hoech
and (e) quantification of Oct-4-positive and -negative cells expres
corresponding Oct-4 expression (red), (h) Hoechst 33342 nuclear sta
cells (k) negative for Oct-4 expression (red), (l) Hoechst 33342 nuc
quantification of Oct-4-positive and -negative cells expressing cyclin
Oct-4 expression (red), (q) Hoechst 33342 nuclear staining (blue), and
for Oct-4 expression (red), (u) Hoechst 33342 nuclear staining (blue
Oct-4-positive and -negative cells expressing cyclin D3 in hESC cultucounterparts (GCTM-2HIGH cells), with 81±4.1% of cells in S
phase and only low cell proportions in G0/G1 (8±1.7%) and
G2/M (11±0.8%) phases, as previously described (Savatier et
al., 1994, 1996, 2002; Stead et al., 2002). The SSEA-1LOW and
SSEA-1NEG cells displayed a progressive reduction in the
S-phase fraction and an increase in the G0/G1 fraction,
although no significant cell cycle differences were observed
between the three subpopulations.
Differentiation inversely changes the expression of
G1- and S-phase-promoting cyclins in hESC cultures
HESC grown on MEF for 7 days in serum-free medium with
FGF-2 were stained for stem cell marker Oct-4 and cyclins
D1, D2, D3, E, or A by indirect double immunocytochemistry.
Spontaneously differentiated, Oct-4-negative human cells
were distinguished from MEF by their distinct nuclear
morphology when counterstained with the nuclear dye
Hoechst 33248. Human Oct-4-positive cells were uniformly
negative for cyclin D1 (Figs. 2a–2d), cyclin D2 (Figs. 2f–2i),
and cyclin D3 (Figs. 2o–2r). However, 99±1.0% of Oct-4-
positive cells costained with cyclin E in the nucleus and
cytoplasm (Figs. 3a–3e) and 60±1.5% costained with cyclin A
only in the nucleus (Figs. 4a–4e).
In the population of differentiated human cells (Oct-4-
negative cells that showed loss of hESC morphology), 23±
7.3% expressed cyclin D1 (Figs. 2a–2e), 22±5.4% expressed
cyclin D2 (Figs. 2j–2n), and 32±4.1% stained with an
antibody to cyclin D3 (Figs. 2s–2w). In all cells D-type
cyclins were localized to the nucleus. Cyclin E was present in
19±3.6% of Oct-4-negative cells (Fig. 3e) and the cyclin A
antibody stained 18±7.9% (Fig. 4e). In both cases the
staining was faint and mostly nuclear. Thus, hESC lack D-
type cyclins, and the expression of these proteins is switched
on upon differentiation, as in mESC. The high cycling
fraction of hESC compared to differentiated cells is
associated with the expression of cyclins E and A, and the
lower S-phase fraction of differentiated cells is coupled with
a reduction in the proportion of cells positive for these
cyclins. Using a flow-cytometric immunoassay we deter-
mined the association of cyclin A expression with cell cycle
phase (PI-counterstained nuclei) for both GCTM-2HIGH and
GCTM-2NEG cells (Fig. 4f). In both cell fractions the mode of
cyclin A expression was identical, rising during S and G2
phases followed by downregulation in M phase and absence
in G0/G1. In accordance with quantitative analysis per-
formed on Oct-4-positive and Oct-4-negative cells by in-
direct immunofluorescence, the GCTM-2HIGH cell fraction
contained a significantly higher proportion of cells positive
for cyclin A (50±3.4%) compared to the GCTM-2NEG cell
fraction (18±5.6%) (Fig. 4f).and Oct-4 showing (a) hESC and adjoining differentiated cells
st 33342 nuclear staining (blue), and (d) cyclin D1 staining (green)
sing cyclin D1 in hESC cultures. (f) HESC (phase contrast), (g)
ining (blue), and (i) cyclin D2 staining (green), (j) differentiated
lear staining (blue), and (m) cyclin D2 presence (green) and (n)
D2 in hESC cultures. (o) HESC (phase contrast), (p) corresponding
(r) cyclin D3 staining (green), (s) differentiated cells (t) negative
), and (v) cyclin D3 presence (green) and (w) quantification of
res. Scale bars, 100 μm.
49Differentiation in human embryonic stem cells
Figure 3 Double immunofluorescence staining for cyclin E and Oct-4 showing (a) human ES and differentiated cells, (b)
corresponding Oct-4 expression (red), (c) Hoechst 33342 nuclear staining (blue), (d) cyclin E staining for both cell types (green),
and (e) quantification of Oct-4-positive and -negative cells expressing cyclin E in hESC cultures. Scale bars, 100 μm.
Figure 4 Double immunofluorescence staining for cyclin A and Oct-4 showing (a) human ES and differentiated cells (phase contrast),
(b) corresponding Oct-4 expression (red), (c) Hoechst 33342 nuclear staining (blue), (d) cyclin A staining across both cell types (green),
and (e) quantification of Oct-4-positive and -negative cells expressing cyclin A in hESC cultures. (f) Flow-cytometric analysis of cyclin A
expression versus nuclear staining intensity for GCTM-2HIGH and GCTM-2NEG cells. Both cell subpopulations show cyclin A staining
consistent with a steady upregulation during S and G2 phases followed by downregulation at M phase and absence of expression in
G0/G1. Scale bars, 100 μm.
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51Differentiation in human embryonic stem cellspRb undergoes a G1-specific dephosphorylation
event in hESC
Another property, which has been correlated with the fast
proliferation and truncated G1 of mouse ES cells, is the
absence of hypophosphorylated pRb protein (Savatier et al.,
1994). In somatic cells pRb is reversibly hyperphosphorylatedFigure 5 (a) Immunosorted GCTM-2HIGH cells were used for an
sphorylated and hyperphosphorylated pRb (Ser795) protein species.
protein and Oct-4 showing (b) human ES and differentiated cells (
Hoechst 33342 nuclear staining (blue), and (e) hypophosphorylate
photographs (63 and times;) showing (f) hESC nuclei stained with Ho
(red), and (h) nuclear staining for hypophosphorylated pRb protein
expressing hypophosphorylated pRb in hESC cultures. Scale bars,
sphorylated pRb (Ser 795) and Oct-4 showing (j) human ES and dif
Hoechst 33342 nuclear staining (blue), and (m) hyperphosphorylated
Quantification of Oct-4-positive and -negative cells expressing hypein S and G2/M phases and becomes hypophosphorylated at
the end of M phase and during most of the G1 phase
(Buchkovich et al., 1989). We asked if hypophosphorylated
pRb protein was present in hESC (GCTM-2HIGH cells) that were
shown to have the highest proliferative fraction and the
smallest cell fraction with 2N DNA content (G0/G1 cells).
Immunosorted GCTM-2HIGH cell lysates were examined byimmunoblot analysis showing the presence of both hypopho-
Double immunofluorescence staining for hypophosphorylated Rb
phase contrast), (c) corresponding Oct-4 expression (red), (d)
d pRb staining across both cell types (green). Oil immersion
echst 33342 (blue), (g) cells positive for stem cell marker Oct-4
(green). (i) Quantification of Oct-4-positive and -negative cells
100 μm. Double immunofluorescence staining for hyperpho-
ferentiated cells, (k) corresponding Oct-4 expression (red), (l)
pRb staining for both cell types (green). Scale bars, 100 μm. (n)
rphosphorylated pRb in hESC cultures.
Figure 6 Triple label immunofluorescence showing (a) the mutual exclusion of cyclin A positivity (green) and the presence of
hypophosphorylated pRb protein (red) on (b) hESC identified by positivity for GCTM-2 (blue) and (c) ES cell morphology. The same
analysis was performed on differentiated human cells showing (d) the absence of cyclin A staining (green), the majority of cells
positive for hypophosphorylated pRb (red) and (e) the lack of GCTM-2 expression, (f) accompanied by a differentiated cell morphology.
Scale bars, 100 μm.
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bodies: pRb-Ser 795, which detects pRb hyperphosphorylated
by cyclinE/CDK-2 or cyclin A/CDK-2 complexes (Zarkowska
and Mittnacht, 1997), and pMG99-549, which recognizes the
hypophosphorylated form characteristic of early G1 cells
(Juan et al., 1998). These immunoreagents detected both
isoforms of pRb in GCTM-2HIGH hESC (Fig. 5a). Immunofluor-
escence analysis using pMG99-549 (Figs. 5b–5h) and pRb-Ser
795 (Figs. 5j–5m) antibodies detected 20±3.7% (Fig. 5i) and
99.9±0.1% (Fig. 5n) of cells, respectively, also positive for
Oct-4. 65±4.5% of differentiated (Oct-4-negative) human
cells were positive for hypophosphorylated pRb (Fig. 5i) and
incidentally had the highest percentage of cells in G1, as
previously shown by cell cycle distribution analysis (GCTM-
2NEG cells). Only 12±2.1% of Oct-4-negative human cells were
positive for hyperphosphorylated pRb (Fig. 5n), as expected of
cells predominantly residing in G0/G1. Given that cyclin AFigure 7 (a) Colony size and cell morphology of hESC treated for 6
Cell cycle distribution analysis of GCTM-2HIGH cells after 6 days of tre
proportion of RV-treated cells in G0/G1was significantly higher (⁎pb0.
proportion of RV-treated cells in G2/M was significantly lower (⁎pb0
(d) Cell cycle profile of DMSO-treated control hESC at day 6 showing
profile of RV-treated hESC at day 6 showing the accumulation of ce
remaining in G2/M. (f) The percentages of GCTM-2-positive cells und
showing no significant change in the percentage of proteoglycan-positi
with (g) DMSOor (h) CDK-4 inhibitor II (1,4-dimethoxy-9-thio(10H)-acri
after 6 days of treatment with DMSO (gray bars) or CDK-4 inhibitor II (1
cells in G0/G1, S, and G2/M were not significantly different compared
profile of DMSO-treated control hESC at day 6 showing distributions of
inhibitor II-treated hESC at day 6 showing no change in cell cycle distrib
and CDK-4 inhibitor II treatment conditions after 6 days of culture s
positive cells. (m) Triple immunolabeling for GCTM-2 (orange), Oct-4 (b
(n) RV treatment conditions after 6 days of growth. Scale bars, 100
proportion of GCTM-2/Oct-4 double-positive hESC expressing the G1-sp
a significantly higher (⁎⁎pb0.01) proportion of hypophosphorylated pRexpression is associated with the S and G2/M phases of the cell
cycle in both GCTM-2HIGH and GCTM-2NEG cells, we expected
that the presence of a G1-specific hypophosphorylated form of
pRb should never coincide with cyclin A-positive cells. Indirect
triple immunocytochemistry analysis confirmed that cells
positive for GCTM-2 and hypophosphorylated pRb were all
negative for cyclin A (Figs. 6a–6c). The expression of
hypophosphorylated pRb and cyclin A in cells negative for
GCTM-2 were also mutually exclusive (Figs. 6d–6f).
Induction of G1-S delay in hESC upregulates
dephosphorylated pRb and promotes the loss of
Oct-4 in hESC cultures
The above findings showed that hESC have a unique mode of
cell cycle control whereby the lack of D-type cyclins is
accompanied by a significant G0/G1 cell fraction. Thedays with DMSO or (b) Roscovitine (RV; 30 μM) CDK-2 inhibitor. (c)
atment with DMSO (gray bars) or RV (30 μM) (hatched bars). The
05) compared to the proportion of DMSO control cells at day 6. The
.05) compared to the proportion of DMSO control cells at day 6.
distributions of cells in G0/G1, S, and G2/M phases. (e) Cell cycle
lls in G0/G1 and S, with a significantly lower proportion of cells
er the DMSO and RV treatment conditions after 6 days of culture
ve cells. Colony size and cellmorphology of hESC treated for 6 days
done, 10μM). (i) Cell cycle distribution analysis of GCTM-2HIGH cells
0 μM) (hatched bars). The proportions of CDK-4 inhibitor II-treated
to the proportions of DMSO control cells at day 6. (j) Cell cycle
cells in G0/G1, S, and G2/M phases. (k) Cell cycle profile of CDK-4
ution. (l) The percentages ofGCTM-2 positive cells under the DMSO
howing no significant change in the percentage of proteoglycan-
lue), andhypophosphorylated retinoblastomaunder theDMSOand
μm. (o) RV treatment yielded a significantly higher (⁎⁎pb0.01)
ecific, hypophosphorylated form of pRb at day 6 and (p) produced
b-expressing cells positive for GCTM-2 but negative for Oct-4.
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kinase for passage through the R point, defined by pRb
rephosphorylation before completion of the G1-S traverse.
We proceeded to test this model further by asking if hESCcould be delayed at the G1-S border by the administration of
a CDK-2-specific pharmacological inhibitor. HESC cultures
were grown for 6 days in medium supplemented with the
pharmacological CDK-2 inhibitor Roscovitine (RV; 30-μM, IC50
55Differentiation in human embryonic stem cells700 nM) or DMSO carrier and analyzed for cell cycle structure
by flow-cytometric immunoassay.
After 6 days of growth, the RV-treated cultures displayed
visibly smaller hESC colonies compared to the DMSO-treated
control (Figs. 7a and 7b). Flow-cytometric analysis showed
that the RV-treated GCTM-2HIGH subpopulation retained a
significantly higher proportion of cells in G0/G1 (34±2.5%)
compared to the DMSO condition (19±3.2%) (Figs. 7c–7e).
The proportion of S-phase GCTM-2HIGH cells between RV and
DMSO treatments was not significantly different, while the
percentage of cells in G2/M was significantly lower in RV-
treated GCTM-2HIGH cells (8±3.6%) compared to the control
(18±4.5%) (Figs. 7c–7e). After 6 days of inhibitor treatment,
no significant differences in the proportions of GCTM-2-
positive cells were observed between RV-(52±3.1%) and
DMSO-(46±3.5%) treated cultures (Fig. 7f). Consistent with
the absence of cyclin D1, D2, and D3 expression, no
significant effect on GCTM-2HIGH cell cycle structure or
GCTM-2-positive cell content was observed after 6 days of
treatment with the pharmacological CDK-4 inhibitor II (1,4-
dimethoxy-9-thio(10H)-acridone at 10 μM, IC50 200 nM)
compared to carrier treatment alone (Figs. 7g–7l). By
contrast the same CDK-4 inhibition significantly delayed
the GCTM-2NEG cell subfraction in G1 compared to carrier-
treated cells, reinforcing our conclusions that differentiation
restores CDK-4 dependency and activates restriction point
control (Supplementary Fig. 3). Treatment of MEF cells with
CDK-4 inhibitor II for 48 h also resulted in a significant delay
of cells in G1 compared to carrier-treated cells (Supplemen-
tary Fig. 4).
We next performed indirect triple immunostaining and
confocal imaging for the hypophosphorylated form of pRb
together with stem cell markers GCTM-2 and Oct-4 on hESC
cultures treated for 6 days with RV or DMSO. Reflecting the
significantly higher GCTM-2HIGH G0/G1 cell content after RV
treatment, the inhibitor also significantly increased the
proportion of GCTM-2/Oct-4 double-positive cells expressing
the hypophosphorylated form of pRb protein by twofold
(Figs. 7m–7o) (48±3.3%) compared to the untreated control
(24±6.5%). Confocal imaging analysis of DMSO- or RV-treated
hESC colonies showed the presence of cells double positive
for GCTM-2 and hypophosphorylated pRb that had lost Oct-4
expression (Figs. 7m and 7n). We quantified the number of
these cells under either condition and found that RV
treatment yielded a significantly higher proportion of cells
positive for the G1-specific, hypophosphorylated form of
pRb, which retained the Oct-4-negative, GCTM-2-positiveFigure 8 (a) With FGF-2 treatment, cell number at experimental d
cells. Dotted line represents control levels in the absence of FGF-2
morphology and no differentiation in the presence of FGF-2 and (c
without FGF-2 treatment. HESC colonies at day 15 show (d) minima
defined edges with FGF-2 treatment and (e) loss of ES cell colony mo
defined colony borders in the absence of FGF-2. Scale bars, 100 μm.
cells treated with FGF-2 were less differentiated at days 7 and 15
experiments confirmed that the effect at day 15 was significant (pb
apoptosis, cells for each treatment were analyzed with flow-cyto
GCTM-2 expression intensity, ranging in percentile intervals from 20
for cell cycle structure, showing the proportions of cells in G0/G1,
culture, and (i) apoptosis assayed by the TUNEL method at day 15
⁎⁎pb0.01).immunophenotype (14.8±3.3%), compared to DMSO treat-
ment alone (6.3±0.9%) (Fig. 7p). Inhibiting G1 phase
transition was therefore sufficient to initiate the onset of
differentiation.
Varying biological effects of FGF-2 on cell
subpopulations in hESC cultures
The existence of a significant G1 phase in hESC, along with a
potential regulatory mechanism in the form of cyclin A and
pRb, suggested that in contrast to mESC, mitogens might act
on these cells to regulate the G1/S phase transition. FGF-2
facilitates the clonal derivation of hESC lines and supports
their maintenance in serum-free medium (Amit et al., 2000;
Xu et al., 2005). Further work has shown that FGF-2 and its
receptors are expressed in hESC (Dvorak et al., 2005) and
that the factor stimulates the secretion of beneficial
molecules in MEF that support hESC in culture while
suppressing the release of differentiation-inducing activity
(Greber et al., 2007). However, the possibility that FGF-2
modulates other biological effects on hESC has not been
examined. We cultured hESC on MEF under serum-free
conditions with or without FGF-2 (4 ng/ml) supplementation
for short-term (7 days) and prolonged (15 days) culture
periods. We found no difference at experimental day 6
between the numbers of colonies formed from cell clumps
passaged into medium with (2670 colonies) or without FGF-2
(2625 colonies). We next determined the number of cells
present at day 7 and day 15 in FGF-2-treated and untreated
cultures. No differences in vital cell numbers were observed
between the two conditions at day 7; however, in the
presence of FGF-2 the number of live cells at day 15 was over
twofold higher than in untreated controls (Fig. 8a). Thus the
effect of FGF-2 withdrawal on hESC becomes manifest only
gradually.
At day 7 the absence of FGF-2 had marginal effects on
hESC morphology, with some colonies developing disorga-
nized edges (Figs. 8b and 8c). By day 15, untreated colonies
appeared mostly differentiated, with extensive areas of cyst
formation compared to FGF-2 treated colonies (Figs. 8d and
8e). Quantitative flow-cytometric analysis confirmed these
observations (Fig. 8f). As expected, on day 7 GCTM-2 labeling
profiles were not significantly different with (63±1.9%) or
without FGF-2 treatment (59±0.8%). However, at 15 days,
FGF-2 significantly increased (66±4.1%) the proportion of
GCTM-2-positive cells over untreated cells (39±7.5%). Thus,
FGF-2 is not critical for short-term ES cell propagationay 15 was significantly (⁎⁎pb0.01) higher compared to untreated
arbitrarily set to 1. HESC colonies at day 7 show (b) tight colony
) minimal differentiation and slight distortion of colony edges
l differentiation in the center of the colony and preservation of
rphology and widespread cystic and differentiated areas without
(f) Flow-cytometric profiles of GCTM-2 expression showing that
than untreated cells. Statistical analysis of three independent
0.01). To determine the effects of FGF-2 on cell proliferation or
metric immunoassays and subdivided into groups according to
to 100. Cells treated and untreated with FGF-2 were analyzed
S, and G2/M phases at (g) day 7 of culture and (h) day 15 of
. Significant differences are indicated by asterisks (⁎pb0.05 or
56 A.A. Filipczyk et al.although its inhibitory effect on spontaneous differentiation
is necessary to maintain ES cells in serum-free culture for
prolonged periods.
We also examined the effects of FGF-2 on the cell cycle
profiles of cell subpopulations with different GCTM-2
expression levels. After 7 days of culture in the absence of
FGF-2, cell cycle profiles across the entire GCTM-2 labeling
distribution were not significantly different from those of
treated cells (Fig. 8g). By day 15 a moderate but significantly
higher proliferative fraction was observed in GCTM-2NEG
(first quintile) cells and GCTM-2LOW cells in the second and
third quintiles (13%) in the presence of FGF-2 (Fig. 8h). By
contrast growth factor treatment did not exert a mitogenic
effect on GCTM-2HIGH cells (fifth quintile) at day 15. GCTM-
2NEG cells showed a reduced proliferative fraction at day 15
compared to day 7. This reduction was more than twofold
greater for untreated cells (27%) than for those stimulated by
FGF-2 (13%) (Fig. 8h).
In light of the increased cell number observed and
proportion of GCTM-2-positive cells in the presence of FGF-
2, we examined if the factor inhibited apoptosis by a flow-
cytometric immunoassay detecting DNA fragmentation as
part of the apoptotic program by the terminal deoxynucleo-
tidyltransferase dUTP nick-end labeling (TUNEL) method. As
a positive control, short-wave UV treatment of hESC cultures
caused a 2.5-fold increase in apoptosis to be detected by this
method (not shown). Cells grown for 15 days in the presence
or absence of FGF-2 were compared for apoptotic cell rates
across GCTM-2 expression (Fig. 8i). The significant increases
in cell number and amount of GCTM-2-positive cells at day 15
were not due to an antiapoptotic effect elicited by FGF-2
stimulation. The level of apoptosis at this time interval
remained relatively unchanged under both treated (21±2.7)
and untreated (21±2.6) conditions over the entire GCTM-2
distribution.Discussion
Spontaneous differentiation occurs under most hESC growth
conditions, producing a heterogeneous culture. To conduct
accurate and unambiguous cell cycle analyses we fractio-
nated the hESC population using an antibody recognizing a
cell surface marker (GCTM-2) of undifferentiated hESC.
GCTM-2HIGH cells showed the highest proliferative and lowest
G0/G1 cell cycle fraction. GCTM-2LOW or GCTM-2NEG cells
displayed progressively lower proliferation fractions and
conversely higher proportions of cells in G0/G1. Complemen-
tary double flow cytometry analysis showed that GCTM-2HIGH
cells best represented a homogeneous subpopulation uni-
formly expressing Oct-4 and other markers of pluripotency.
Cell populations with lower levels of the marker were
progressively more contaminated with cells negative for
Oct-4. Consequently, analyses of key cell cycle components
in hESC were performed on GCTM-2HIGH or Oct-4-positive
cells.
Human Oct-4-positive cells did not express cyclin D1, D2,
or D3 at the protein level and accordingly, treatment with
the CDK-4 inhibitor 1,4-dimethoxy-9-thio(10H)-acridone did
not affect the cell cycle distribution of the GCTM-2HIGH cell
subpopulation. The repression of D-type cyclins may be
necessary for the maintenance of an undifferentiatedphenotype in hESC. In the mouse embryo, expression of
cyclins D1, D2, and D3 is established prior to the onset of
gastrulation and correlates with lineage-specific commit-
ment (Wianny et al., 1998; Ciemerych et al., 2002).
However, cyclin D1 was cited as a pluripotent-specific gene
in hESC microarray publications (Sato et al., 2003; Rao et al.,
2004). Cyclin D2 and CDK-4 were also recently found to be
highly expressed in hESC (Becker et al., 2006, 2007). How-
ever, these studies used a heterogeneous mixture of hESC
and differentiated cells for analysis and examined global
expression of mRNA, not protein at the single-cell level, as in
this study.
Only after the loss of Oct-4 and the onset of differentia-
tion does cyclin D1, D2, and D3 expression become evident.
In accord with the role of D-type cyclins as growth factor-
responsive catalysts for G1 progression in somatic cells
(Bartek et al., 1996), we found that only cells negative for
Oct-4 expression became responsive to mitogenic stimula-
tion by FGF-2. Undifferentiated hESC do not respond to FGF-
2 with a change in their cell cycle profile, and the factor has
no influence on their survival. Instead FGF-2 inhibits hESC
differentiation. Our data are consistent with findings from
previous reports investigating the direct and/or indirect
roles of this growth factor on hESC, although the examination
of FGF-2-dependent effects on the rate of stem cell division
or apoptosis is novel in our study (Xu et al., 2005; Kim et al.,
2005; Greber et al., 2007).
Surprisingly, the cell cycle characteristics of hESC appear
to be unlike those described for mouse ES cells (Savatier et
al., 1994, 2002), epiblast cells (Mac Auley et al., 1993),
embryonic germ cells (Resnick et al., 1992), and embryonal
carcinoma cells (Mummery et al., 1987), in which DNA
replication and mitotic division occur in rapid succession
without fully formed gap phases. In mESC, these features
have been attributed to high levels of cell-cycle-indepen-
dent cyclin E/CDK-2, cyclin A/CDK-2 kinase activities, which
drive proliferation and ensure the permanent inactivation of
pRb protein (Stead et al., 2002). While cyclin E activity is
permanent in hESC, cyclin A is expressed periodically. When
resolved against cell cycle phases by flow cytometry, cyclin
A upregulation was consistent with its requirement for S-
phase traverse and peak activity at prometaphase allowing
mitotic entry (Yam et al., 2002) in both GCTM-2HIGH and
GCTM-2NEG cells.
The downregulation of cyclin A in the G1 phase of hESC
may lower CDK-2 kinase activity to a level acceptable for a
“restriction-point-like” pRb activation event, shown to occur
by coimmunostaining and immunoblot analyses. The active
form of this tumor suppressor is a growth-inhibitory brake
mechanism (Weinberg, 1995) and maintains cells in G1 by
repressing the transcription of S-phase-promoting genes
(Ludlow et al., 1993; Harbour and Dean, 2000). We propose
that G1-specific activation of pRb is responsible for the
significantly larger G1 fraction observed in GCTM-2 HIGH cells
compared to SSEA-1HIGH cells. Interestingly, the loss of SSEA-
1 did not correlate with significant changes in cell cycle
structure. Consistent with our findings, mESC, both positive
and negative for SSEA-1, injected into eight-stage mouse
embryos still differentiate into epiblast cells in high numbers
(Furusawa et al., 2004) and the loss of SSEA-1 in vitrowas not
always shown to associate with the extent of cell differ-
entiation (Cui et al., 2004).
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kinase activity and initiate G1-S traverse by rephospho-
rylating pRb, but what is the likely function of a pRb-
dependent G1 checkpoint in these cells? HESC differentiation
resulted in lower cyclin E/A expression and the exaggeration
of G1 coupled with the presence of active pRb in the majority
of hESC marker-negative cells. The activation of pRb in
cooperation with extrinsic signals has been shown to
promote fate determination of neural stem cells (Jori et
al., 2007) and to control strictly the lineage commitment and
differentiation of progenitors in muscle, heart, and blood
(reviewed in Goodrich, 2006; Galderisi et al., 2006). The G1-
specific pRb activation event was a potential divergence
point at which hESC could be directed toward differentiation
over self-renewal.
We speculated that if the compromise of CDK-2 kinase
activity in hESC would delay these cells at the G1-S border
and increase the expression of active pRb, it may also
promote the induction of differentiation. Treatment with
the CDK-2 inhibitor RV resulted in the appearance of
smaller “dwarf” hESC colonies and produced a twofold
increase in GCTM-2HIGH cells in G1. We also observed a
significant decrease in the proportion of GCTM-2HIGH cells in
M phase, consistent with findings indicating the importance
of cyclin A/CDK-2 for S-phase progression and entry into
mitosis (reviewed in Yam et al., 2002). Our triple staining
and confocal imaging analyses showed that the proportion
of G1-residing, active pRb-expressing cells positive for
GCTM-2 that lost Oct-4 expression was 2.5-fold higher in
hESC subjected to CDK-2-dependent cell cycle delay. G1
perturbation and prolonged pRb activation appeared to
promote the disappearance of Oct-4, a stem cell marker
essential for the maintenance of pluripotency that is lost
with the onset of differentiation in mESC and hESC
(reviewed in Pesce et al., 1999; Pesce and Scholer, 2000;
Pera et al., 2000; Carpenter et al., 2003). Interestingly, the
GCTM-2+/Oct-4 and minus; cells were found previously only in
the GCTM-2LOW and GCTM-2NEG subpopulations displaying
significantly higher G1- and lower S-phase contents com-
pared to GCTM-2HIGH cells. Given these observations one
cannot exclude the possibility that CDK-2, which has broad
activity throughout the cell cycle, may also regulate self-
renewal by mechanisms unrelated to G1/S control.
However, G1 elongation and prolonged pRb activation in
hESC shown here to associate with the loss of Oct-4 are likely
to be a signaling mechanism for extrinsic factors to initiate
early differentiation in hESC. Proteins known to differentiate
hESC, like BMP-2 (Pera et al., 2004; Pal and Khanna, 2007),
can elevate cyclin-dependent kinase inhibitor p21Cip1,
downregulating CDK-2 activity and promoting pRb activation
in cells (Ghosh-Choudhury et al., 2000). The link between
p21 upregulation, pRb activation, and cell differentiation is
in turn firmly established during lineage commitment in
blood and muscle (reviewed in Kitzmann and Fernandez,
2001; Steinman, 2002; Furukawa, 2002).
These data provide the first evidence whereby the
perturbation of G1 and consequently the prolonged activa-
tion of pRb provide the necessary signals to initiate the
onset of hESC differentiation. Our results are in agreement
with accumulating evidence showing active pRb as a
master regulator required for the induction of tissue-
specific gene expression during the early differentiation ofvarious cell lineages (reviewed in De Falco et al., 2006;
Skapek et al., 2006). We propose that the active pRb
checkpoint in the hESC G1 is also a control point for the
initiation of differentiation, commitment, and conversion
to a conventional mode of cell cycle control found in
somatic cells.
Materials and methods
Cell culture and treatments
The derivation and routine culture of the stocks of HES-2,
HES-3, and HES-4 cell lines were previously described
(Reubinoff et al., 2000). To produce larger numbers of cells
required for these experiments, hESC were grown on
mitomycin-treated MEF in the presence of 80% Dulbecco's
modified Eagles medium F-12 formulation (Invitrogen, CA,
USA), 0.1 mM β-mercaptoethanol, 1% nonessential amino
acids, 2 mM L-glutamine, and 20% KnockOut SR serum
replacer medium (Gibco BRL). Culture medium was supple-
mented with human recombinant FGF-2 (4 ng/ml) (Amit et
al., 2000). Cells were passaged by enzymatic dissociation
using Collagenase IA (1 mg/ml) (Sigma-Aldrich, MO, USA) and
mechanical shearing of whole ES cell colonies for large-scale
propagation. The pharmacological CDK-2 inhibitor Roscov-
itine (30 μM, IC50 700 nM), pharmacological CDK-4 inhibitor II
(10 μM, IC50 200 nM), or DMSO control solutions were
administered into culture media 24 h after hESC subculture
and replenished daily with medium changes for 6 days of
growth before cell cycle analyses. OKO mouse ES cells used
for this study were cultured on 0.1% gelatin in 80% Dulbecco's
modified Eagles medium (Invitrogen), 0.1 mM β-mercap-
toethanol, 1% nonessential amino acids, 2 mM L-glutamine,
and 20% bovine serum (Gibco BRL). The medium was
supplemented with LIF (10 ng/ml).
BrdU proliferation assay
HES-2 and HES-4 cells were incubated with 1:1000 BrdU
labeling reagent (Roche, Mannheim, Germany) for 2 h at
37 °C and 5% CO2. HESC were harvested as mentioned above
and dissociated into single-cell suspension with trypsin
(0.5 mg/ml), fixed in 100% methanol for 1 h, and denatured
in 4 N HCl for 10 min. The acidic solution was neutralized by
repeatedly washing cells with fetal calf serum (FCS)
(Hyclone, UT, USA)-containing medium. The cells were
then labeled with GCTM-2 indirectly conjugated to allophy-
cocyanin and then anti-BrdU antibody directly conjugated to
FLUOS (Roche) and finally counterstained with propidium
iodide (2 μg/ml). An aliquot of cells was retained to measure
the extent of MEF feeder cells in sample material using anti-
mouse Thy1.2 directly conjugated to phycoerythrin. The
cells were analyzed on a MoFlo flow cytometer using Summit
v3.1 sort control software.
TUNEL apoptotic assay
HES-2, HES-3, and HES-4 cells colonies were harvested and
dissociated into single-cell suspension as mentioned above.
Fixation of the cells was performed in 1% paraformaldehyde
for 15 min on ice followed by a PBS wash and refixation in 70%
58 A.A. Filipczyk et al.ethanol for 24 h at −20 °C. Cells were washed free of the
fixative in PBS and treated with a TUNEL reaction solution for
1 h at 37 °C prepared according to the manufacturer's
instructions (Pharmingen, NJ, USA). TUNEL-positive cells
were stained by a fluorescein-conjugated antibody supplied
in the reaction solution. The cells were then labeled with
GCTM-2 indirectly conjugated to Alexa-Fluor 647 (Molecular
Probes, OR, USA). The extent of MEF contamination and the
flow-cytometric analysis were performed as described
above.
Immunofluorescence
Cells grown on slides were fixed and permeabilized with 100%
ethanol, 100% methanol, or acetone/H2O 9/1 and immunos-
tained with antibodies raised against the following stem cell
markers as described previously (Pera et al., 2003): GCTM-2
(this laboratory), TRA-1-60 (gift from P. Andrews, University
of Sheffield), SSEA-1 (Developmental Studies Hybridoma
Bank), and Oct-4 (Santa Cruz Biotechnology, CA, USA). Cell
cycle analysis was conducted using antibodies raised against
cyclin D1 (DCS-6) and underphosphorylated retinoblastoma
protein (G99-549) (Pharmingen); cyclin D2 (34B1-3), cyclin
D3 (18B6-10), and cyclin E (M-20) (all from Santa Cruz
Biotechnology); cyclin A (mouse IgG1) and hyperphosphory-
lated (Ser 795) retinoblastoma protein (Cell Signaling
Technology, MA, USA); and cyclin A (mouse IgG2a) (Sigma).
Secondary antibody fluorochromes used were FITC, Cy3, and
Cy5 (Jackson Immunoresearch); and Alexa-Fluor-350, Alexa-
Fluor-488, and Alexa-Fluor-568. Where required, nuclei were
counterstained with Hoechst 33342 (Chemicon, CA, USA) and
specimens mounted using antifading solution (Vectashield,
Australia). Specificity of immunoreagents was verified by the
absence of staining in isotype-specific negative controls.
Photographic images were captured at 20 °C using immuno-
fluorescence or phase-contrast microscopy using an upright
Leica DMR microscope equipped with a mercury arc lamp.
The objectives used were a 20 and times; phase with a
numerical aperture (na=0.60), a 40× phase objective
(na=0.75), and a 63× oil immersion objective (na=1.32).
Image files were saved in TIFF format on a Leica DC200
photographic program or Leica SP2 AOBS confocal imaging
software (Mannheim, Germany) and uniformly adjusted
alongside control images for appropriate viewing brightness
or contrast with Adobe PhotoShop v5.5 image software.
Quantitation of fluorescently stained cells was performed on
three replicate slides for each experiment by counting at
least 500 cells per slide in each fluorescence channel.
FACS analysis and cell sorting
Cells were dissociated into single-cell suspension as pre-
viously described and immunostained live for GCTM-2 or
fixed and permeabilized with 100% methanol for Oct-4
labeling. Antibodies raised to GCTM-2 or Oct-4 were applied
(100 μl antibody/106 cells), and the cells were labeled on ice
for 30 min, washed with FCS-containing medium, and
incubated on ice for 30 min with an FITC-conjugated
secondary antibody (Dako, Glostrup, Denmark). Cells sorted
on the basis of GCTM-2 fluorescence intensity were collected
in plastic ampoules, filled with FCS-containing medium tominimize cell lysis, and stored immediately on ice until lysis
treatment.
Western blot analysis
GCTM-2HIGH HES-3 cells were lysed with RIPA lysis buffer
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% deoxycholate, 1%
Triton X-100, protease inhibitor tablet Cocktail II 1:10 from
Roche, 0.4 mM NaF, 0.4 mM NaVO4, 0.1 mM EDTA, 0.1 mM
EGTA, 7.5 μg/ml aprotinin, 70 μg/ml PMSF) for 5 min at 4 °C.
The lysate was clarified by centrifugation at 14,000g for
10 min at 4 °C and protein concentrations were determined
by Bradford assay using a Bio-Rad kit. Equal lysate volumes
were combined with 2×reducing loading buffer before the
sample was denatured for 5 min in a boiling water bath. Cell
lysates were resolved on a 6% SDS Tris-glycine polyacrylamide
gel and electrotransferred to PVDF membranes, which were
blocked in 5% skim milk, 0.1% Tween 20 for 3 h at room
temperature or overnight at 4 °C. Membranes were
incubated for 2 h with retinoblastoma antibodies (G99-549
or Ser 795) at room temperature, washed four times with PBS
containing 0.1% Tween 20 (PBST), and incubated for 1 h with
a horseradish peroxidase (HRP)-conjugated secondary anti-
body (Dako) in PBST. HRP activity was detected with an ECL
detection kit (Amersham, Buckinghamshire, UK) on Kodak
film.
Statistical analysis
Experiments were performed at least three times. Data were
analyzed as the means±SD of at least three independent
experiments.
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